|
Market Closed -
Toronto S.E.
23:00:00 27/10/2026 +03
|
5-day change | 1st Jan Change | ||
| 4.570 CAD | +2.47% |
|
+10.12% | -5.19% |
| 10-01 | HLS Therapeutics Inc. Announces Board and Committee Changes | CI |
| 09-24 | HLS Therapeutics Gets TSX Acceptance to Increase Normal Course Issuer Bid | MT |
Company Valuation: HLS Therapeutics Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 384.6 | 235.2 | 95.92 | 86.84 | 109.9 | 99.05 | - | - |
| Change | - | -38.85% | -59.22% | -9.47% | 26.6% | -9.9% | - | - |
| Enterprise Value (EV) | 384.6 | 235.2 | 95.92 | 86.84 | 109.9 | 99.05 | 99.05 | 99.05 |
| Change | - | -38.85% | -59.22% | -9.47% | 26.6% | -9.9% | 0% | 0% |
| P/E | -28.9x | -9.95x | -3.52x | -4.41x | -9.01x | -15.7x | -46.5x | 36.2x |
| PBR | - | 1.88x | - | 1.22x | - | 1.87x | 1.82x | - |
| PEG | - | -0.1x | -0.2x | 0.2x | 0.2x | 0.3x | 0.7x | -0x |
| Capitalization / Revenue | 6.41x | 3.83x | 1.52x | 1.53x | 1.98x | 1.7x | 1.52x | 1.26x |
| EV / Revenue | 0x | 0x | 0x | 0x | 0x | 1.7x | 1.52x | 1.26x |
| EV / EBITDA | 0x | 0x | 0x | 0x | 0x | 5.21x | 4.39x | 3.01x |
| EV / EBIT | -0x | -0x | -0x | -0x | -0x | -25.4x | -142x | 13.4x |
| EV / FCF | 0x | 0x | 0x | 0x | 0x | 7.39x | - | - |
| FCF Yield | 3.27% | 7.18% | 16.4% | 9.2% | 15.4% | 13.5% | - | - |
| Dividend per Share 2 | - | - | 0.7398 | - | - | - | - | - |
| Rate of return | - | - | 24.7% | - | - | - | - | - |
| EPS 2 | -0.41 | -0.73 | -0.85 | -0.62 | -0.39 | -0.2067 | -0.07 | 0.09 |
| Distribution rate | - | - | -87% | - | - | - | - | - |
| Net sales 1 | 60.01 | 61.47 | 63.07 | 56.62 | 55.5 | 58.34 | 65.06 | 78.65 |
| EBITDA 1 | 26.33 | 23.83 | 21.05 | 16.65 | 19.62 | 19.03 | 22.57 | 32.9 |
| EBIT 1 | -6.284 | -13.5 | -10.35 | -7.686 | -4.106 | -3.9 | -0.7 | 7.4 |
| Net income 1 | -13.12 | -23.6 | -27.53 | -19.66 | -12.43 | -5.47 | -2.164 | 3.1 |
| Net Debt | - | - | - | - | - | - | - | - |
| Reference price 2 | 11.853 | 7.263 | 2.991 | 2.731 | 3.515 | 3.254 | 3.254 | 3.254 |
| Nbr of stocks (in thousands) | 32,451 | 32,384 | 32,071 | 31,793 | 31,274 | 30,442 | - | - |
| Announcement Date | 3/17/22 A | 3/16/23 A | 3/14/24 A | 3/13/25 A | 3/12/26 A | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -15.74x | - | - | - | 99.05M | |
| 37.66x | 13.18x | 27.98x | 0.53% | 1,143B | |
| 39.33x | 6.61x | 18.6x | 1.99% | 647B | |
| 37.45x | 8.4x | 17.37x | 2.4% | 506B | |
| 21.46x | 5.22x | 12.98x | 2.51% | 384B | |
| 103.38x | 5.8x | 24.86x | 2.4% | 350B | |
| 21.99x | 5.69x | 13.69x | 2.94% | 293B | |
| 22.31x | 4.51x | 12.87x | 1.96% | 265B | |
| 28.42x | 7.28x | 13.03x | 2.25% | 242B | |
| -45.78x | 7.1x | 27.53x | 2.07% | 197B | |
| Average | 25.05x | 7.09x | 18.77x | 2.12% | 402.76B | |
| Weighted average by Cap. | 35.27x | 8.35x | 20.48x | 1.8% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- HLS Stock
- Valuation HLS Therapeutics Inc.
Select your edition
All financial news and data tailored to specific country editions
